0001104659-16-151946.txt : 20161025
0001104659-16-151946.hdr.sgml : 20161025
20161025163346
ACCESSION NUMBER: 0001104659-16-151946
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161025
FILED AS OF DATE: 20161025
DATE AS OF CHANGE: 20161025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vitae Pharmaceuticals, Inc
CENTRAL INDEX KEY: 0001157602
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043567753
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 502 WEST OFFICE CENTER DR
CITY: FORT WASHINGTON
STATE: PA
ZIP: 19034
BUSINESS PHONE: 215-461-2000
MAIL ADDRESS:
STREET 1: 502 WEST OFFICE CENTER DR
CITY: FORT WASHINGTON
STATE: PA
ZIP: 19034
FORMER COMPANY:
FORMER CONFORMED NAME: Vitae Pharmaceuticals Inc
DATE OF NAME CHANGE: 20050118
FORMER COMPANY:
FORMER CONFORMED NAME: CONCURRENT PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20010815
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sable Carole
CENTRAL INDEX KEY: 0001604066
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36617
FILM NUMBER: 161950735
MAIL ADDRESS:
STREET 1: C/O SCYNEXIS, INC.
STREET 2: 3501 C TRICENTER BOULEVARD
CITY: DURHAM
STATE: NC
ZIP: 27713
4
1
a4.xml
4
X0306
4
2016-10-25
1
0001157602
Vitae Pharmaceuticals, Inc
VTAE
0001604066
Sable Carole
C/O VITAE PHARMACEUTICALS, INC.
502 WEST OFFICE CENTER DR.
FORT WASHINGTON
PA
19034
0
1
0
0
Chief Medical Officer
Stock Option (Right to Buy)
10.51
2016-10-25
4
D
0
150000
10.49
D
2026-06-05
Common Stock
150000
0
D
Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option.
This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option June 6, 2017 (the "Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
/s/ Carole Sable
2016-10-25